Overview
Ustekinumab, marketed under the brand name Stelara, is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines involved in inflammatory and immune responses. It is primarily used to treat autoimmune diseases such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. Developed by Janssen Biotech, ustekinumab has gained widespread use due to its efficacy in reducing symptoms and improving quality of life for patients. Approved by the FDA in 2009, ustekinumab has since been adopted globally, with numerous clinical trials supporting its safety and effectiveness. Its mechanism of action involves binding to the p40 subunit shared by IL-12 and IL-23, thereby inhibiting their interaction with cell surface receptors and reducing downstream inflammatory signaling.
Physical and Chemical Properties
Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody with a molecular weight of approximately 148.6 kDa. It is formulated as a clear to slightly opalescent, colorless to light yellow solution for subcutaneous or intravenous administration. The antibody is produced in a Chinese hamster ovary (CHO) cell line through recombinant DNA technology. The solution typically has a pH of 5.7 to 6.3 and contains excipients such as L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. These components ensure stability and solubility, making the drug suitable for long-term storage under refrigerated conditions. The absence of preservatives necessitates single-use vials or prefilled syringes to prevent contamination.
Main Applications
Ustekinumab is indicated for the treatment of several autoimmune conditions. In plaque psoriasis, it reduces skin lesions and scaling by targeting the underlying inflammatory pathways. For psoriatic arthritis, it alleviates joint pain and stiffness, improving mobility and reducing disease progression. In Crohn's disease, ustekinumab helps maintain remission and reduces flare-ups by modulating the immune response in the gastrointestinal tract. Off-label uses are also being explored, including for ulcerative colitis and other inflammatory bowel diseases. Clinical trials have demonstrated its potential in these areas, though regulatory approvals vary by region. The drug's ability to selectively inhibit IL-12 and IL-23 without broadly suppressing the immune system makes it a valuable option for patients who do not respond to conventional therapies.
Safety and Storage
Ustekinumab must be stored at 2°C to 8°C (36°F to 46°F) and protected from light. Freezing or shaking the solution can denature the protein, rendering it ineffective. The drug is supplied in single-dose vials or prefilled syringes to ensure sterility, as it lacks preservatives. Once removed from refrigeration, it should be used within a specified timeframe to maintain potency. Safety considerations include monitoring for infections, as ustekinumab can increase susceptibility to bacterial, viral, and fungal pathogens. Patients should be screened for tuberculosis (TB) before starting treatment. Other potential adverse effects include hypersensitivity reactions, headaches, and fatigue. Healthcare providers must weigh these risks against the benefits, particularly in immunocompromised individuals.
B2B Procurement Guide
Procuring ustekinumab for B2B purposes requires attention to regulatory compliance, cold chain logistics, and supplier reliability. Buyers should verify that the product meets regional approval standards (e.g., FDA, EMA) and is sourced from authorized distributors. Bulk purchases may offer cost advantages, but storage capacity must align with the drug's refrigeration requirements. Negotiating contracts with manufacturers or wholesalers can secure favorable pricing, especially for long-term supply agreements. It is advisable to request certificates of analysis (CoA) and stability data to ensure product quality. Additionally, buyers should consider insurance coverage for temperature excursions during transit, as deviations can compromise efficacy. Partnering with logistics providers experienced in biologics is critical to maintaining the cold chain from factory to end-user.
Related Manufacturers
- 主营：依洛尤单抗、人cx3c趋化因子
- 主营：依洛尤单抗、生物化工试剂、中间体、帕罗韦德中间体
- 主营：对照品、标准品、当归酸酐、依洛尤单抗、佛手柑内酯、新当归内酯、补骨脂甲素、补骨脂乙素、羟基芍药苷、阿魏酸松柏酯、水合氧化前胡素、豆甾醇葡萄糖苷
- 主营：碘海醇、葡甲胺、氨甲环酸、依洛尤单抗、盐酸柔红霉素、甘油磷酸钠、海藻糖、葡乙胺、古龙酸、托吡酯、潮霉素B、替卡西林钠克拉维酸钾、星孢菌素、盐酸阿霉素、碘帕醇